4cmo: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "4cmo" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
The entry 4cmo is ON HOLD | The entry 4cmo is ON HOLD until Paper Publication | ||
Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A. | Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A. | ||
Description: Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 2-((1R)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-N-methylbenzamide | Description: Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 2-((1R)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-N-methylbenzamide | ||
Revision as of 08:11, 2 April 2014
Unreleased structure
The entry 4cmo is ON HOLD until Paper Publication
Authors: McTigue, M., Deng, Y., Liu, W., Brooun, A., Stewart, A.
Description: Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor 2-((1R)-1-((3-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl) oxy)ethyl)-4-fluoro-N-methylbenzamide
